alpha-Lipoic Acid as Adjunctive Treatment for Schizophrenia A Randomized Double-Blind Study

Background/PurposeThere is evidence for low endogenous antioxidant levels and oxidative imbalance in patients with schizophrenia. A previous open-label study with alpha-lipoic acid (ALA), a potent antioxidant, improved patients' negative and cognitive symptoms and markers of lipid peroxidation. Here we report the results of a randomized double-blind, placebo-controlled study to verify the response of patients with schizophrenia to adjunctive treatment with ALA (100 mg/d) in a 4-month follow-up.MethodsWe conducted a 16-week, double-blind, placebo-controlled study of ALA at 100 mg/d dosages. We compared negative and positive symptoms, cognitive function, extrapyramidal symptoms, body mass index, and oxidative/inflammatory parameters between placebo and control groups.ResultsWe found no significant improvement in body mass index, cognition, psychopathology, antipsychotic adverse effects, or oxidative stress and inflammation in the experimental group compared with placebo. The whole group of patients improved in several measures, indicating a strong placebo effect in this population. A surprising finding was a significant decrease in red blood cells, white blood cells, and platelets in the group treated with ALA.ConclusionsThe decrease in red blood cells, white blood cells, and platelet counts requires further investigation and attention when prescribing ALA for patients with schizophrenia.

Automated summary

This study aimed to verify the therapeutic effect of alpha-lipoic acid (ALA) supplementation in patients with schizophrenia. The results showed no significant improvement in body parameters, cognitive function, psychopathology, antipsychotic adverse effects, or oxidative stress and inflammation in the experimental group compared with placebo. A significant decrease in red blood cells, white blood cells, and platelet counts in the ALA treatment group was observed, which requires further investigation.